EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	11806	prostaglandin	USPAT	OR	OFF	2008/01/30 14:08
L2	1666	prostaglandin and leukotriene	USPAT	OR	OFF	2008/01/30 14:08
L3	1146	prostaglandin and leukotriene and inhibitor	USPAT	OR	OFF	2008/01/30 14:08
L4	12	prostaglandin and leukotriene and inhibitor and medicament.clm.	USPAT	OR	OFF	2008/01/30 14:08
S1	1	"20020035137"	US-PGPUB; USPAT	OR	OFF	2008/01/30 10:32
S2	1	"20070249649"	US-PGPUB; USPAT	OR	OFF	2008/01/30 10:37
S3	1	("6376546").PN.	USPAT; USOCR	OR	OFF	2008/01/30 10:39
S4	1	("6867320").PN.	USPAT; USOCR	OR	OFF	2008/01/30 10:39
S5	1	("5136090").PN.	USPAT; USOCR	OR	OFF	2008/01/30 10:43
S6	758	560/56.ccls.	US-PGPUB; USPAT	OR	OFF	2008/01/30 10:47
S7	265	560/56.ccls. and 562/466.ccls.	US-PGPUB; USPAT	OR	OFF	2008/01/30 10:47
S8	39	560/56.ccls. and 562/466.ccls. and 564/172.ccls.	US-PGPUB; USPAT	OR	OFF	2008/01/30 10:48
S9	3	560/56.ccls. and 562/466.ccls. and 564/172.ccls. and alkanoic	US-PGPUB; USPAT	OR	OFF	2008/01/30 10:48

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTASEL1626

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	AUG 06	CAS REGISTRY enhanced with new experimental property tags
NEWS 3	AUG 06	FSTA enhanced with new thesaurus edition
NEWS 4	AUG 13	CA/CAplus enhanced with additional kind codes for granted patents
NEWS 5	AUG 20	CA/CAplus enhanced with CAS indexing in pre-1907 records
NEWS 6	AUG 27	Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB
NEWS 7	AUG 27	USPATOLD now available on STN
NEWS 8	AUG 28	CAS REGISTRY enhanced with additional experimental spectral property data
NEWS 9	SEP 07	STN AnaVist, Version 2.0, now available with Derwent World Patents Index
NEWS 10	SEP 13	FORIS renamed to SOFIS
NEWS 11	SEP 13	INPADOCDB enhanced with monthly SDI frequency
NEWS 12	SEP 17	CA/CAplus enhanced with printed CA page images from 1967-1998
NEWS 13	SEP 17	CAplus coverage extended to include traditional medicine patents
NEWS 14	SEP 24	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS 15	OCT 02	CA/CAplus enhanced with pre-1907 records from Chemisches Zentralblatt
NEWS 16	OCT 19	BEILSTEIN updated with new compounds
NEWS 17	NOV 15	Derwent Indian patent publication number format enhanced
NEWS 18	NOV 19	WPIX enhanced with XML display format
NEWS 19	NOV 30	ICSD reloaded with enhancements
NEWS 20	DEC 04	LINPADOCDB now available on STN
NEWS 21	DEC 14	BEILSTEIN pricing structure to change
NEWS 22	DEC 17	USPATOLD added to additional database clusters
NEWS 23	DEC 17	IMSDRUGCONF removed from database clusters and STN
NEWS 24	DEC 17	DGENE now includes more than 10 million sequences
NEWS 25	DEC 17	TOXCENTER enhanced with 2008 MeSH vocabulary in MEDLINE segment
NEWS 26	DEC 17	MEDLINE and LMEDLINE updated with 2008 MeSH vocabulary
NEWS 27	DEC 17	CA/CAplus enhanced with new custom IPC display formats
NEWS 28	DEC 17	STN Viewer enhanced with full-text patent content from USPATOLD
NEWS 29	JAN 02	STN pricing information for 2008 now available
NEWS 30	JAN 16	CAS patent coverage enhanced to include exemplified prophetic substances
NEWS 31	JAN 28	USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats
NEWS 32	JAN 28	MARPAT searching enhanced
NEWS 33	JAN 28	USGENE now provides USPTO sequence data within 3 days of publication
NEWS 34	JAN 28	TOXCENTER enhanced with reloaded MEDLINE segment
NEWS 35	JAN 28	MEDLINE and LMEDLINE reloaded with enhancements

NEWS EXPRESS 19 SEPTEMBER 2007: CURRENT WINDOWS VERSION IS V8.2,
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 19 SEPTEMBER 2007.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 09:38:25 ON 30 JAN 2008

=> fil reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 09:38:33 ON 30 JAN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 29 JAN 2008 HIGHEST RN 1001040-86-3
DICTIONARY FILE UPDATES: 29 JAN 2008 HIGHEST RN 1001040-86-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10568185s.str



chain nodes :
7 8 9 10 11 12 22
ring nodes :
1 2 3 4 5 6 13 14 15 16 17 18 19 20 21
chain bonds :
3-7 5-13 6-12 7-8 8-9 9-10 9-11 19-22
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 13-14 13-18 14-15 15-16 16-17 16-19 17-18
17-21 19-20 20-21
exact/norm bonds :
6-12 16-17 16-19 17-21 19-20 19-22 20-21
exact bonds :
3-7 5-13 7-8 8-9
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 9-10 9-11 13-14 13-18 14-15 15-16 17-18

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS
11:CLASS 12:CLASS 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom 22:CLASS

L1 STRUCTURE UPLOADED

=>

=> d
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

```
=> s l1
SAMPLE SEARCH INITIATED 09:38:52 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -       45 TO ITERATE

100.0% PROCESSED       45 ITERATIONS                                 6 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:          498 TO     1302
PROJECTED ANSWERS:               6 TO      266

L2            6 SEA SSS SAM L1

=> s l1 ful
FULL SEARCH INITIATED 09:38:57 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      913 TO ITERATE

100.0% PROCESSED      913 ITERATIONS                               157 ANSWERS
SEARCH TIME: 00.00.01

L3          157 SEA SSS FUL L1

=> fil caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   178.36     178.57

FILE 'CAPLUS' ENTERED AT 09:39:03 ON 30 JAN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)
```

FILE COVERS 1907 - 30 Jan 2008 VOL 148 ISS 5
FILE LAST UPDATED: 29 Jan 2008 (20080129/ED)

=> s l3
L4 2 L3

=> d ibib abs hitstr tot

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:250264 CAPLUS
DOCUMENT NUMBER: 143:229568
TITLE: Preparation of aralkanoates as inhibitors of prostaglandin and leukotriene production.
INVENTOR(S): Shoda, Motoshi; Kuriyama, Hiroshi
PATENT ASSIGNEE(S): Asahi Kasei Pharma Corporation, Japan
SOURCE: PCT Int. Appl., 687 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005016862	A1	20050224	WO 2004-XC11952	20040813
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
WO 2005016862	A1	20050224	WO 2004-JP11952	20040813
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: JP 2003-293590 A 20030814
US 2003-495734P A 20030818
WO 2004-JP11952 A 20040813

GI



I

AB Title compds. {I; L = (unsatd.) C1-3 hydrocarbon chain; X2-X6 = CH, V; ≤1 of X2-X6 = V; V = N, CZ; Z = alkyl, F, Cl, Br, OH, alkoxy, amino, etc.; R = DRx, amino; , D = bond, O, S, SO, SO2, CO; Rx = alkyl, aminoalkyl, etc.; Ar = (substituted) partially or completely unsatd. condensed carbobicyclyl, heterocyclyl; Y = H, alkyl, aminoalkyl, etc.], were prepared Thus, Me 3-{4-cyclopentyloxy-3-(naphthalen-2-yl)phenyl]propionate (preparation outlined) and other I inhibited IL-1β induced PGE2 production by ≥50% at 1.0 μM. [This abstract record is

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
one of 4 records for this document necessitated by the large no. of index entries required to fully index the document and publication system constraints.].

IT 862982-81-8P 862982-92-1P 862983-00-4P
862983-06-0P 862983-12-8P 862983-18-4P
862983-24-2P 862983-28-6P 862983-33-3P
862983-39-9P 862983-45-7P 862983-51-5P
862983-57-1P 862983-61-7P 862983-69-5P
862983-86-6P 862983-94-6P 862984-02-9P
862984-10-9P 862984-18-7P 862984-26-7P
862984-34-7P 862984-40-5P 862984-46-1P
862984-57-4P 862984-63-2P 862984-79-0P
862984-87-0P 862984-95-0P 862985-10-2P
862985-18-0P 862985-26-0P 862985-32-8P
862985-40-8P 862985-53-3P 862985-67-9P
862985-80-6P 862985-96-4P 862986-09-2P
862986-17-2P 862986-25-2P 862986-33-2P
862986-39-8P 862986-45-6P 862986-61-6P
862986-77-4P 862986-82-1P 862986-90-1P
862986-98-9P 862987-06-2P 862987-14-2P
862987-22-2P 862987-28-8P 862987-36-8P
862987-44-8P 862987-48-2P 862987-58-4P
862987-64-2P 862987-70-0P 862987-76-6P
862987-84-6P 862987-88-0P 862987-94-8P
862988-04-3P 862988-10-1P 862988-16-7P
862988-22-5P 862988-30-5P 862988-34-9P
862990-16-7P 862990-20-3P 862990-37-2P
862990-43-0P 862990-49-6P 862990-59-8P
862990-69-0P 862990-77-0P 862990-85-0P
862990-95-2P 862991-05-7P 862991-15-9P
862991-25-1P 862991-33-1P 862991-43-3P
862991-51-3P 862991-61-5P 862991-69-3P
862991-79-5P 862991-95-5P 862992-03-8P
862992-09-4P 862992-17-4P 862992-25-4P
862992-33-4P 862992-39-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aralkanoates as inhibitors of prostaglandin and leukotriene production)

RN 862982-81-8 CAPLUS
CN Benzenepropanoic acid, 3-bromo-4-(cyclopentylamino)-5-(1-methyl-1H-indol-5-yl)- (CA INDEX NAME)



RN 862982-92-1 CAPLUS
CN Benzenepropanoic acid, 3-amino-5-(1-methyl-1H-indol-5-yl)-4-[methyl(4-methylcyclohexyl)amino]- (CA INDEX NAME)

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 862983-00-4 CAPLUS
CN Benzenepropanoic acid, 4-(cyclopentylmethylamino)-3-(methylamino)-5-(1-methyl-1H-indol-5-yl)- (CA INDEX NAME)



RN 862983-06-0 CAPLUS
CN Benzenepropanoic acid, 3-(methylamino)-5-(1-methyl-1H-indol-5-yl)-4-(methylpropylamino)- (CA INDEX NAME)



RN 862983-12-8 CAPLUS
CN Benzenepropanoic acid, 3-(methylamino)-5-(1-methyl-1H-indol-5-yl)-4-[methyl(1-methylethyl)amino]- (CA INDEX NAME)



RN 862983-18-4 CAPLUS

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
CN Benzenepropanoic acid, 4-[(2,3-dihydro-1H-inden-2-yl)methylamino]-3-(methylamino)-5-(1-methyl-1H-indol-5-yl)- (CA INDEX NAME)



RN 862983-24-2 CAPLUS
CN Benzenepropanoic acid, 4-(cyclohexylmethylamino)-3-(methylamino)-5-(1-methyl-1H-indol-5-yl)- (CA INDEX NAME)



RN 862983-28-6 CAPLUS
CN Benzenepropanoic acid, 3-(methylamino)-5-(1-methyl-1H-indol-5-yl)-4-[methyl(4-methylcyclohexyl)amino]- (CA INDEX NAME)



RN 862983-33-3 CAPLUS
CN Benzenepropanoic acid, 4-(cyclopentylmethylamino)-3-(dimethylamino)-5-(1-methyl-1H-indol-5-yl)- (CA INDEX NAME)

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 862992-33-4 CAPLUS
CN Benzenepropanoic acid, 3-amino-4-[(2,3-dihydro-1H-inden-2-yl)methylamino]-5-(1-methyl-1H-indol-5-yl)- (CA INDEX NAME)



RN 862992-39-0 CAPLUS
CN Benzenepropanoic acid, 3-amino-4-(cyclohexylmethylamino)-5-(1-methyl-1H-indol-5-yl)- (CA INDEX NAME)



L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
yl)phenyl]propionate (prepn. outlined) and other I inhibited IL-1β induced PGE2 prodn. by ≥50% at 1.0 μM. [This abstr. record is one of 4 records for this document necessitated by the large no. of index entries required to fully index the document and publication system constraints.].

IT 861933-19-9P 861933-21-3P 861933-44-0P
861933-50-8P 861933-72-4P 861933-80-4P
861933-92-8P 861934-02-3P 861934-04-5P
861934-32-9P 861934-34-1P 861934-36-3P
861934-38-5P 861934-40-9P 861934-42-1P
861934-71-6P 861934-79-4P 861934-81-8P
861934-83-0P 861934-85-2P 861934-86-3P
861934-87-4P 861934-89-6P 861934-91-0P
861934-93-2P 861935-07-1P 861935-19-5P
861935-26-4P 861935-28-6P 861935-46-8P
861935-50-4P 861935-58-2P 861935-66-2P
861935-74-2P 861935-99-1P 861936-07-4P
861936-13-2P 861936-23-4P 861936-35-8P
861936-39-2P 861936-47-2P 861936-58-5P
861936-82-5P 861936-99-4P 861937-12-4P
861937-20-4P 861937-25-9P 861937-29-3P
861937-31-7P 861937-33-9P 861937-35-1P
861937-37-3P 861940-83-2P 861940-91-2P
861940-97-8P 861941-03-9P 861941-17-5P
861941-37-9P 861941-53-9P 861941-59-5P
861941-67-5P 861941-73-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aralkanoates as inhibitors of prostaglandin and leukotriene production)

RN 861933-19-9 CAPLUS
CN Benzenepropanoic acid, 3-(1-methyl-1H-indol-5-yl)-4-[(phenylmethyl)amino]- (CA INDEX NAME)



RN 861933-21-3 CAPLUS
CN Benzenepropanoic acid, 3-(1-ethyl-1H-indol-5-yl)-4-[(phenylmethyl)amino]- (CA INDEX NAME)

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:250263 CAPLUS
DOCUMENT NUMBER: 143:193812
TITLE: Preparation of aralkanoates as inhibitors of prostaglandin and leukotriene production.
INVENTOR(S): Shoda, Motoshi; Kuriyama, Hiroshi
PATENT ASSIGNEE(S): Asahi Kasei Pharma Corporation, Japan
SOURCE: PCT Int. Appl., 687 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005016862	A1	20050224	WO 2004-XB11952	20040813
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
WO 2005016862	A1	20050224	WO 2004-JP11952	20040813
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.:	JP 2003-293590	A	20030814
	US 2003-495734P	A	20030818
	WO 2004-JP11952	A	20040813

GI



I

AB Title compds. [I; L = (unsatd.) C1-3 hydrocarbon chain; X2-X6 = CH, V; ≤1 of X2-X6 = V; V = N, CZ; Z = alkyl, F, Cl, Br, OH, alkoxy, amino, etc.; R = DRx, amino; D = bond, O, S, SO, SO2, CO; Rx = alkyl, aminoalkyl, etc.; Ar = (substituted) partially or completely unsatd. condensed carbobicyclyl, heterocyclyl; Y = H, alkyl, aminoalkyl, etc.], were prepared Thus, Me 3-[4-cyclopentyloxy-3-(naphthalen-2-

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 861933-44-0 CAPLUS
CN Benzenepropanoic acid, 3-(1-methyl-1H-indol-5-yl)-4-[methyl(phenylmethyl)amino]- (CA INDEX NAME)



RN 861933-50-8 CAPLUS
CN Benzenepropanoic acid, 4-[[(4-fluorophenyl)methyl]amino]-3-(1-methyl-1H-indol-5-yl)- (CA INDEX NAME)



RN 861933-72-4 CAPLUS
CN Benzenepropanoic acid, 4-[[(4-fluorophenyl)methyl]methylamino]-3-(1-methyl-1H-indol-5-yl)- (CA INDEX NAME)



RN 861933-80-4 CAPLUS
CN Benzenepropanoic acid, 4-[ethyl[(4-fluorophenyl)methyl]amino]-3-(1-methyl-1H-indol-5-yl)- (CA INDEX NAME)

=> fil reg
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	11.38	189.95

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-1.60	-1.60

FILE 'REGISTRY' ENTERED AT 09:39:46 ON 30 JAN 2008

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 29 JAN 2008 HIGHEST RN 1001040-86-3
DICTIONARY FILE UPDATES: 29 JAN 2008 HIGHEST RN 1001040-86-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10568185.str



chain nodes :
7 8 9 10 11 12
ring nodes :
1 2 3 4 5 6 13 14 15 16 17 18 19 20 21
chain bonds :
3-7 5-13 6-12 7-8 8-9 9-10 9-11
ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 13-14 13-18 14-15 15-16 16-17 16-19 17-18
17-21 19-20 20-21
exact/norm bonds :
6-12 16-17 16-19 17-21 19-20 20-21
exact bonds :
3-7 5-13 7-8 8-9
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 9-10 9-11 13-14 13-18 14-15 15-16 17-18

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS
11:CLASS 12:CLASS 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom

L5 STRUCTURE UPLOADED

=> d
L5 HAS NO ANSWERS
L5 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l5
SAMPLE SEARCH INITIATED 09:40:29 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 45 TO ITERATE

100.0% PROCESSED 45 ITERATIONS 10 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

```
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:          498 TO     1302
PROJECTED ANSWERS:              11 TO      389

L6           10 SEA SSS SAM L5

=> s l5 ful
FULL SEARCH INITIATED 09:40:34 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      913 TO ITERATE

100.0% PROCESSED      913 ITERATIONS                          244 ANSWERS
SEARCH TIME: 00.00.01

L7          244 SEA SSS FUL L5

=> fil caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   178.36     368.31

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                     0.00      -1.60

FILE 'CAPLUS' ENTERED AT 09:40:37 ON 30 JAN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 30 Jan 2008  VOL 148 ISS 5
FILE LAST UPDATED: 29 Jan 2008  (20080129/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l7
L8           2 L7

=> fil reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.48     368.79

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                     0.00      -1.60
```

FILE 'REGISTRY' ENTERED AT 09:40:42 ON 30 JAN 2008

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 29 JAN 2008 HIGHEST RN 1001040-86-3
DICTIONARY FILE UPDATES: 29 JAN 2008 HIGHEST RN 1001040-86-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10568185b.str



chain nodes :
7 8 9 10 11 18
ring nodes :
1 2 3 4 5 6 12 13 14 15 16 17
chain bonds :
3-7 5-12 6-11 7-8 8-9 9-10 9-18
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 12-13 12-17 13-14 14-15 15-16 16-17
exact/norm bonds :
6-11 9-10 9-18 15-16
exact bonds :
3-7 5-12 7-8 8-9
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 12-13 12-17 13-14 14-15 16-17

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS
11:CLASS 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:CLASS

L9 STRUCTURE UPLOADED

=> d
L9 HAS NO ANSWERS
L9 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l9
SAMPLE SEARCH INITIATED 09:41:53 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 93 TO ITERATE

100.0% PROCESSED 93 ITERATIONS 50 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 1282 TO 2438
PROJECTED ANSWERS: 849 TO 1831

L10 50 SEA SSS SAM L9

=> s l9
SAMPLE SEARCH INITIATED 09:41:57 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 93 TO ITERATE

100.0% PROCESSED 93 ITERATIONS 50 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 1282 TO 2438
PROJECTED ANSWERS: 849 TO 1831

L11 50 SEA SSS SAM L9

=> s l9 ful
FULL SEARCH INITIATED 09:42:04 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 1812 TO ITERATE

100.0% PROCESSED 1812 ITERATIONS 1227 ANSWERS
SEARCH TIME: 00.00.01

L12 1227 SEA SSS FUL L9

=> fil caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	178.82	547.61

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-1.60

FILE 'CAPLUS' ENTERED AT 09:42:11 ON 30 JAN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 30 Jan 2008 VOL 148 ISS 5
FILE LAST UPDATED: 29 Jan 2008 (20080129/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l12
L13 2 L12

=> fil reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION

FULL ESTIMATED COST 0.96 548.57

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE ENTRY TOTAL SESSION

CA SUBSCRIBER PRICE 0.00 -1.60

FILE 'REGISTRY' ENTERED AT 09:43:35 ON 30 JAN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 29 JAN 2008 HIGHEST RN 1001040-86-3
DICTIONARY FILE UPDATES: 29 JAN 2008 HIGHEST RN 1001040-86-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10568185d.str



chain nodes :
7 8 9 10 11 12 13
ring nodes :
1 2 3 4 5 6
chain bonds :
3-7 5-12 6-11 7-8 8-9 9-10 9-13
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6
exact/norm bonds :
5-12 6-11 9-10 9-13
exact bonds :
3-7 7-8 8-9
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS
11:CLASS 12:Atom 13:CLASS

L14 STRUCTURE UPLOADED

=> d
L14 HAS NO ANSWERS
L14 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l14
SAMPLE SEARCH INITIATED 09:44:12 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 5321 TO ITERATE

37.6% PROCESSED 2000 ITERATIONS 34 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 102046 TO 110794
PROJECTED ANSWERS: 1239 TO 2379

L15 34 SEA SSS SAM L14

=> s l14 full
FULL SEARCH INITIATED 09:44:15 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 106353 TO ITERATE

100.0% PROCESSED 106353 ITERATIONS 1263 ANSWERS
SEARCH TIME: 00.00.02

L16 1263 SEA SSS FUL L14

=> fil caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	178.36	726.93

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-1.60

FILE 'CAPLUS' ENTERED AT 09:44:19 ON 30 JAN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 30 Jan 2008 VOL 148 ISS 5
FILE LAST UPDATED: 29 Jan 2008 (20080129/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l16
L17 5 L16

=> d ibib abs hitstr tot

L17 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:1212638 CAPLUS
DOCUMENT NUMBER: 147:502356
TITLE: Imidazolecarboxamide compounds as inhibitors of c-Fms kinase and their preparation, pharmaceutical compositions and use in the treatment of diseases
INVENTOR(S): Illig, Carl R.; Ballentine, Shelley K.; Chen, Jinsheng; Desjarlais, Renee Louise; Meegalla, Sanath K.; Wall, Mark; Wilson, Kenneth
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 151pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2007249649	A1	20071025	US 2007-736635	20070418
WO 2007124318	A1	20071101	WO 2007-US66864	20070418
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRIORITY APPLN. INFO.:			US 2006-793694P	P 20060420
			US 2006-871171P	P 20061221

OTHER SOURCE(S): MARPAT 147:502356
GI



I II

AB The invention is directed to compds. of formula I, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-Fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, colon cancer, stomach cancer, hairy cell leukemia and non-small lung carcinoma;

L17 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, Paget's disease, and other diseases in which bone resorption mediates morbidity including arthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compds. of formula I, are also provided. Compds. of formula I wherein W is (un)substituted azoles and (un)substituted furanyl; R2 is cycloalkyl spiro-substituted cycloalkenyl, heterocyclyl, spiro-substituted piperidinyl, etc.; Z is H, F and Me; J is CH and N; Z is (un)substituted C1-6 alkyl, alkenyl, propenylamine, etc.; and their solvates, hydrates, tautomers, and pharmaceutically acceptable salts thereof, are claimed. Example compd. II was prepd. by a multistep procedure (procedure given). All the invention compds. were evaluated for their c-Fms kinase inhibitory activity. From the assay, it was detd. that compd. II exhibited an IC50 value of 0.0589 μM.

IT 954422-60-7P 954422-61-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of imidazolecarboxamide compds. as c-Fms kinase inhibitors useful in treatment and prevention of diseases)

RN 954422-60-7 CAPLUS
CN Benzenepropanoic acid, 4-[[(5-cyano-1H-imidazol-2-yl)carbonyl]amino]-3-(1-cyclohexen-1-yl)- (CA INDEX NAME)



RN 954422-61-8 CAPLUS
CN Benzenepropanoic acid, 4-[[[5-(aminocarbonyl)-1H-imidazol-2-yl]carbonyl]amino]-3-(1-cyclohexen-1-yl)- (CA INDEX NAME)



L17 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:250264 CAPLUS
DOCUMENT NUMBER: 143:229568
TITLE: Preparation of aralkanoates as inhibitors of prostaglandin and leukotriene production.
INVENTOR(S): Shoda, Motoshi; Kuriyama, Hiroshi
PATENT ASSIGNEE(S): Asahi Kasei Pharma Corporation, Japan
SOURCE: PCT Int. Appl., 687 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005016862	A1	20050224	WO 2004-XC11952	20040813
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
WO 2005016862	A1	20050224	WO 2004-JP11952	20040813
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:			JP 2003-293590	A 20030814
			US 2003-495734P	A 20030818
			WO 2004-JP11952	A 20040813

GI



I

AB Title compds. [I; L = (unsatd.) C1-3 hydrocarbon chain; X2-X6 = CH, V; ≤1 of X2-X6 = V; V = N, CZ; Z = alkyl, F, Cl, Br, OH, alkoxy, amino, etc.; R = DRx, amino; D = bond, O, S, SO, SO2, CO; Rx = alkyl, aminoalkyl, etc.; Ar = (substituted) partially or completely unsatd. condensed carbobicyclyl, heterocyclyl; Y = H, alkyl, aminoalkyl, etc.], were prepared Thus, Me 3-[4-cyclopentyloxy-3-(naphthalen-2-

L17 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
yl)phenyl]propionate (prepn. outlined) and other I inhibited IL-1β induced PGE2 prodn. by ≥50% at 1.0 μM. [This abstr. record is one of 4 records for this document necessitated by the large no. of index entries required to fully index the document and publication system constraints.].

IT 862982-48-7P 862982-53-4P 862982-59-0P
862982-64-7P 862982-68-1P 862982-72-7P
862982-75-0P 862982-79-4P 862982-81-8P
862982-83-0P 862982-86-3P 862982-88-5P
862982-90-9P 862982-92-1P 862982-94-3P
862982-96-5P 862982-98-7P 862982-99-8P
862983-00-4P 862983-01-5P 862983-02-6P
862983-03-7P 862983-04-8P 862983-05-9P
862983-06-0P 862983-07-1P 862983-08-2P
862983-09-3P 862983-10-6P 862983-11-7P
862983-12-8P 862983-13-9P 862983-14-0P
862983-15-1P 862983-16-2P 862983-17-3P
862983-18-4P 862983-19-5P 862983-20-8P
862983-21-9P 862983-22-0P 862983-23-1P
862983-24-2P 862983-25-3P 862983-26-4P
862983-27-5P 862983-28-6P 862983-29-7P
862983-30-0P 862983-31-1P 862983-32-2P
862983-33-3P 862983-34-4P 862983-35-5P
862983-36-6P 862983-37-7P 862983-38-8P
862983-39-9P 862983-40-2P 862983-41-3P
862983-42-4P 862983-43-5P 862983-44-6P
862983-45-7P 862983-46-8P 862983-47-9P
862983-48-0P 862983-49-1P 862983-50-4P
862983-51-5P 862983-52-6P 862983-53-7P
862983-54-8P 862983-55-9P 862983-56-0P
862983-57-1P 862983-58-2P 862983-59-3P
862983-60-6P 862983-61-7P 862983-62-8P
862983-63-9P 862983-64-0P 862983-65-1P
862983-66-2P 862983-67-3P 862983-68-4P
862983-69-5P 862983-70-8P 862983-71-9P
862983-72-0P 862983-73-1P 862983-75-3P
862983-76-4P 862983-77-5P 862983-78-6P
862983-79-7P 862983-80-0P 862983-81-1P
862983-82-2P 862983-83-3P 862983-84-4P
862983-85-5P 862983-86-6P 862983-87-7P
862983-88-8P 862983-89-9P 862983-90-2P
862983-91-3P 862983-92-4P 862983-93-5P
862983-94-6P 862983-95-7P 862983-96-8P
862983-97-9P 862983-98-0P 862983-99-1P
862984-00-7P 862984-01-8P 862984-02-9P
862984-03-0P 862984-04-1P 862984-05-2P
862984-06-3P 862984-07-4P 862984-08-5P
862984-09-6P 862984-10-9P 862984-11-0P
862984-12-1P 862984-13-2P 862984-14-3P
862984-15-4P 862984-16-5P 862984-17-6P
862984-18-7P 862984-19-8P 862984-20-1P
862984-21-2P 862984-22-3P 862984-23-4P
862984-24-5P 862984-25-6P 862984-26-7P
862984-27-8P 862984-28-9P 862984-29-0P
862984-30-3P 862984-31-4P 862984-32-5P
862984-33-6P 862984-34-7P 862984-35-8P
862984-36-9P 862984-37-0P 862984-38-1P
862984-39-2P 862984-40-5P 862984-41-6P
862984-42-7P 862984-43-8P 862984-44-9P
862984-45-0P 862984-46-1P 862984-47-2P

L17 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:250263 CAPLUS
DOCUMENT NUMBER: 143:193812
TITLE: Preparation of aralkanoates as inhibitors of prostaglandin and leukotriene production.
INVENTOR(S): Shoda, Motoshi; Kuriyama, Hiroshi
PATENT ASSIGNEE(S): Asahi Kasei Pharma Corporation, Japan
SOURCE: PCT Int. Appl., 687 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005016862	A1	20050224	WO 2004-XB11952	20040813
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
WO 2005016862	A1	20050224	WO 2004-JP11952	20040813
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.:
JP 2003-293590 A 20030814
US 2003-495734P A 20030818
WO 2004-JP11952 A 20040813

GI



I

AB Title compds. [I; L = (unsatd.) C1-3 hydrocarbon chain; X2-X6 = CH, V; ≤1 of X2-X6 = V; V = N, CZ; Z = alkyl, F, Cl, Br, OH, alkoxy, amino, etc.; R = DRx, amino; D = bond, O, S, SO, SO2, CO; Rx = alkyl, aminoalkyl, etc.; Ar = (substituted) partially or completely unsatd. condensed carbobicyclyl, heterocyclyl; Y = H, alkyl, aminoalkyl, etc.], were prepared Thus, Me 3-[4-cyclopentyloxy-3-(naphthalen-2-yl)phenyl]propionate (preparation outlined) and other I inhibited IL-1β induced PGE2 production by ≥50% at 1.0 μM. [This abstract record is one of 4 records for this document necessitated by the large no. of index entries required to fully index the document and publication system constraints.].

IT 861933-09-7P 861933-10-0P 861933-11-1P
861933-12-2P 861933-13-3P 861933-14-4P
861933-15-5P 861933-16-6P 861933-17-7P
861933-18-8P 861933-19-9P 861933-20-2P
861933-21-3P 861933-22-4P 861933-23-5P
861933-24-6P 861933-25-7P 861933-26-8P
861933-27-9P 861933-28-0P 861933-29-1P
861933-30-4P 861933-31-5P 861933-32-6P
861933-33-7P 861933-34-8P 861933-35-9P
861933-36-0P 861933-37-1P 861933-38-2P
861933-39-3P 861933-40-6P 861933-41-7P
861933-42-8P 861933-43-9P 861933-44-0P
861933-45-1P 861933-46-2P 861933-47-3P
861933-48-4P 861933-49-5P 861933-50-8P
861933-53-1P 861933-55-3P 861933-57-5P
861933-59-7P 861933-62-2P 861933-64-4P
861933-66-6P 861933-68-8P 861933-70-2P
861933-72-4P 861933-74-6P 861933-76-8P
861933-78-0P 861933-80-4P 861933-82-6P
861933-84-8P 861933-86-0P 861933-88-2P
861933-90-6P 861933-92-8P 861933-93-9P
861933-94-0P 861933-95-1P 861933-96-2P
861933-97-3P 861933-98-4P 861933-99-5P
861934-00-1P 861934-01-2P 861934-02-3P
861934-03-4P 861934-04-5P 861934-05-6P
861934-06-7P 861934-07-8P 861934-08-9P
861934-09-0P 861934-10-3P 861934-11-4P
861934-12-5P 861934-13-6P 861934-14-7P
861934-15-8P 861934-16-9P 861934-17-0P
861934-18-1P 861934-19-2P 861934-20-5P
861934-21-6P 861934-22-7P 861934-23-8P
861934-24-9P 861934-25-0P 861934-26-1P
861934-27-2P 861934-28-3P 861934-29-4P
861934-30-7P 861934-31-8P 861934-32-9P
861934-33-0P 861934-34-1P 861934-35-2P
861934-36-3P 861934-37-4P 861934-38-5P
861934-39-6P 861934-40-9P 861934-41-0P
861934-42-1P 861934-43-2P 861934-44-3P
861934-45-4P 861934-46-5P 861934-47-6P
861934-48-7P 861934-49-8P 861934-50-1P
861934-51-2P 861934-52-3P 861934-53-4P
861934-54-5P 861934-55-6P 861934-56-7P
861934-57-8P 861934-58-9P 861934-59-0P
861934-60-3P 861934-61-4P 861934-62-5P
861934-63-6P 861934-64-7P 861934-65-8P
861934-66-9P 861934-67-0P 861934-68-1P
861934-69-2P 861934-70-5P 861934-71-6P
861934-72-7P 861934-73-8P 861934-74-9P
861934-75-0P 861934-76-1P 861934-77-2P
861934-78-3P 861934-79-4P 861934-80-7P
861934-81-8P 861934-82-9P 861934-83-0P
861934-84-1P 861934-85-2P 861934-86-3P
861934-87-4P 861934-88-5P 861934-89-6P
861934-90-9P 861934-91-0P 861934-92-1P
861934-93-2P 861934-94-3P 861934-95-4P
861934-96-5P 861934-97-6P 861934-98-7P
861934-99-8P 861935-00-4P 861935-01-5P

L17 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
861935-02-6P 861935-03-7P 861935-04-8P
861935-05-9P 861935-06-0P 861935-07-1P
861935-08-2P 861935-09-3P 861935-10-6P
861935-11-7P 861935-12-8P 861935-13-9P
861935-14-0P 861935-15-1P 861935-16-2P
861935-17-3P 861935-18-4P 861935-19-5P
861935-20-8P 861935-21-9P 861935-22-0P
861935-23-1P 861935-24-2P 861935-25-3P
861935-26-4P 861935-27-5P 861935-28-6P
861935-29-7P 861935-30-0P 861935-31-1P
861935-32-2P 861935-33-3P 861935-34-4P
861935-35-5P 861935-36-6P 861935-37-7P
861935-38-8P 861935-39-9P 861935-40-2P
861935-41-3P 861935-42-4P 861935-43-5P
861935-44-6P 861935-45-7P 861935-46-8P
861935-47-9P 861935-48-0P 861935-49-1P
861935-50-4P 861935-51-5P 861935-52-6P
861935-53-7P 861935-54-8P 861935-55-9P
861935-56-0P 861935-57-1P 861935-58-2P
861935-59-3P 861935-60-6P 861935-61-7P
861935-62-8P 861935-63-9P 861935-64-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of aralkanoates as inhibitors of prostaglandin and leukotriene prodn.)

RN 861933-09-7 CAPLUS
CN Benzenepropanoic acid, 3-(2-naphthalenyl)-4-[(phenylmethyl)amino]-, methyl ester (CA INDEX NAME)



RN 861933-10-0 CAPLUS
CN Benzenepropanoic acid, 3-(2-naphthalenyl)-4-[(phenylmethyl)amino]- (CA INDEX NAME)



RN 861933-11-1 CAPLUS
CN Benzenepropanoic acid, 4-[methyl(phenylmethyl)amino]-3-(2-naphthalenyl)-, methyl ester (CA INDEX NAME)

L17 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 861933-12-2 CAPLUS
CN Benzenepropanoic acid, 3-(1-methyl-1H-indol-5-yl)-4-[(1-phenylethyl)amino]-, methyl ester (CA INDEX NAME)



RN 861933-13-3 CAPLUS
CN Benzenepropanoic acid, 4-[[2-(4-fluorophenyl)ethyl]amino]-3-(1-methyl-1H-indol-5-yl)-, methyl ester (CA INDEX NAME)



RN 861933-14-4 CAPLUS
CN Benzenepropanoic acid, 4-[acetyl(phenylmethyl)amino]-3-(1-methyl-1H-indol-5-yl)-, methyl ester (CA INDEX NAME)

L17 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 861960-22-7 CAPLUS
CN Benzenepropanoic acid, 4-amino-3-(1H-indazol-5-yl)-, methyl ester (CA INDEX NAME)



RN 861960-23-8 CAPLUS
CN Benzenepropanoic acid, 4-amino-3-(1-methyl-1H-indazol-5-yl)-, methyl ester (CA INDEX NAME)



L17 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:220307 CAPLUS
DOCUMENT NUMBER: 140:270555
TITLE: Preparation of diarylurea derivatives and their use as chloride channel blockers
INVENTOR(S): Dahl, Bjarne H.; Christophersen, Palle; Engsig, Michael Thyrring; Karsdal, Morten Asser; Foged, Niels Taekker; Jensen, Flemming Reissig
PATENT ASSIGNEE(S): Neurosearch A/s, Den.
SOURCE: PCT Int. Appl., 65 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004022529	A2	20040318	WO 2003-DK575	20030904
WO 2004022529	A3	20040513		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2495284	A1	20040318	CA 2003-2495284	20030904
AU 2003258490	A1	20040329	AU 2003-258490	20030904
EP 1537075	A2	20050608	EP 2003-793605	20030904
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1678573	A	20051005	CN 2003-820985	20030904
JP 2005538152	T	20051215	JP 2004-533214	20030904
NZ 538513	A	20070223	NZ 2003-538513	20030904
MX 2005PA02493	A	20050527	MX 2005-PA2493	20050304
US 2006160856	A1	20060720	US 2005-526208	20050916

PRIORITY APPLN. INFO.:
DK 2002-1306 A 20020905
DK 2002-1310 A 20020905
WO 2003-DK575 W 20030904

OTHER SOURCE(S): MARPAT 140:270555
GI



I

AB ANHCONR1D [A = (un)substituted cyclohexyl, Ph, pyridyl, thienyl, naphthyl, indolyl, pyrazolyl, oxopyrrolidinyl; R1 = H, D = (un)substituted Ph,

L17 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
cyclohexyl, 2-pyridinyl, CHR2CO2H; R2 = (un)substituted Ph; R1D = CH(CO2H)CH2CHR3CH2; R3 = H, OH] were prepd. for use as chloride channel blockers in the treatment of bone metabolic diseases, diseases responsive to modulation of the mast cell or basophil activity, diseases responsive to inhibition of angiogenesis, or sickle cell anemia (no data). Thus, 4-BrC6H4Me was converted to 4-MeC6H4B(OH)2, which was oxidized to 4-HO2CC6H4B(OH)2 and amidated to 4-Me2NCOC6H4B(OH)2. Coupling with 5,2-Br(H2N)C6H3CN gave 4,3-H2N(NC)C6H3C6H4CONMe2-4 which was cyclized to the tetrazole and treated with 3,5-(F3C)2C6H3NCO to give the urea I.

IT 674300-48-2P 674300-49-3P 674300-50-6P
674300-51-7P 674300-52-8P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of diarylurea derivs. and their use as chloride channel blockers)

RN 674300-48-2 CAPLUS
CN Benzenepropanoic acid, 4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]-3-(1H-tetrazol-5-yl)-, methyl ester (9CI) (CA INDEX NAME)



RN 674300-49-3 CAPLUS
CN Benzenepropanoic acid, 4-[[[[3,5-dichlorophenyl]amino]carbonyl]amino]-3-(1H-tetrazol-5-yl)-, methyl ester (9CI) (CA INDEX NAME)



RN 674300-50-6 CAPLUS
CN Benzenepropanoic acid, 4-[[[[3,5-bis(trifluoromethyl)phenyl]amino]carbonyl]amino]-3-(1H-tetrazol-5-yl)-, methyl ester (9CI) (CA INDEX NAME)

L17 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 674300-51-7 CAPLUS
CN Benzenepropanoic acid, 4-[[[[3,5-difluorophenyl]amino]carbonyl]amino]-3-(1H-tetrazol-5-yl)-, methyl ester (9CI) (CA INDEX NAME)



RN 674300-52-8 CAPLUS
CN Benzenepropanoic acid, 4-[[[[2-chlorophenyl]amino]carbonyl]amino]-3-(1H-tetrazol-5-yl)-, methyl ester (9CI) (CA INDEX NAME)



L17 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:171841 CAPLUS
DOCUMENT NUMBER: 136:232543
TITLE: Preparation of amino(oxo)acetic acids as protein tyrosine phosphatase inhibitors
INVENTOR(S): Liu, Gang; Szczepankiewicz, Bruce G.; Pei, Zhonghua; Xin, Zhili; Oost, Thorsten K.; Janowick, David A.
PATENT ASSIGNEE(S): Abbott Laboratories, USA
SOURCE: PCT Int. Appl., 97 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002018323	A2	20020307	WO 2001-US26906	20010829
WO 2002018323	A3	20020627		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 20020035137	A1	20020321	US 2001-918928	20010731
CA 2416740	A1	20020307	CA 2001-2416740	20010829
AU 200185345	A	20020313	AU 2001-85345	20010829
EP 1313696	A2	20030528	EP 2001-964500	20010829
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004531455	T	20041014	JP 2002-523441	20010829
MX 2003PA01304	A	20030905	MX 2003-PA1304	20030212

PRIORITY APPLN. INFO.:		
US 2000-228651P	P	20000829
US 2000-650922	A	20000829
US 2001-918928	A	20010731
WO 2001-US26906	W	20010829

OTHER SOURCE(S): MARPAT 136:232543

AB Compds. R2CR:CRNR6COCOR1 [CR:CR is an aryl, heteroaryl, or heterocycloalkyl ring which may be substituted by alkoxy, alkyl, amido, amino, aminosulfonyl, arylcarbonylamino, cyano, halo, hydroxy, nitro, perfluoroalkoxy, and perfluoroalkyl groups; R1 = alkoxy, alkyl, amino, aminosulfonyl, aryl, arylalkyl, aryloxy, hydroxy, perfluoroalkoxy, perfluoroalkyl; R2 = alkoxy, alkoxycarbonyl, alkyl, amido, amino, carboxy, cyano, nitro, SO3H, PO(OH)2, CH2PO(OH)2, CHFPO(OH)2, CF2PO(OH)2, C(:NH)NH2, and certain 5-membered heterocycles; R6 = alkyl, aryl, arylalkyl, cycloalkenyl, cycloalkenylalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, or (heterocycloalkyl)alkyl] or their therapeutically acceptable salts were prepared as protein tyrosine kinase 1B inhibitors. 2-[(Carboxycarbonyl)(1-naphthyl)amino]benzoic acid and 4-[(carboxycarbonyl)(2-carboxyphenyl)amino]-3-[(E)-3-amino-3-oxo-1-propenyl]-N-(methylsulfonyl)-N-pentyl-L-phenylalaninamide are two of 88 compds. synthesized and claimed. Compds. of the invention inhibit protein tyrosine phosphatase 1B with inhibitory potencies in a range of about of about 0.05 μM to about 21 μM.

IT 402924-66-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

L17 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
(prepn. of amino(oxo)acetic acids as protein tyrosine phosphatase inhibitors)
RN 402924-66-7 CAPLUS
CN Phenylalanine, N-acetyl-4-amino-3-(1-piperidinyl)- (CA INDEX NAME)



=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	27.73	754.66

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-4.00	-5.60

STN INTERNATIONAL LOGOFF AT 09:45:05 ON 30 JAN 2008